VEGF gene therapy for coronary artery disease and peripheral vascular disease

Rasmussen, Henrik Sandvad; Rasmussen, Camilla Sandvad; Macko, Jennifer

doi:10.1016/S1522-1865(02)00158-0

Title: VEGF gene therapy for coronary artery disease and peripheral vascular disease

Full Record
Other Related Research

Abstract

Coronary artery disease (CAD) and peripheral arterial disease (PAD) are significant medical problems worldwide. Although substantial progress has been made in prevention as well as in the treatment, particularly of CAD, there are a large number of patients, who despite maximal medical treatment have substantial symptomatology and who are not candidates for mechanical revascularization. Therapeutic angiogenesis represents a novel, conceptually appealing treatment option. Ad{sub GV}VEGF121.10 (BIOBYPASS) is an adenovector, carrying the transgene encoding for human vascular endothelial growth factor 121 (VEGF{sub 121}). A number of preclinical studies have demonstrated angiogenic activity of BIOBYPASS, not only anatomically but also functionally. Phase I clinical studies have demonstrated that intramyocardial infection of BIOBYPASS in patients with severe CAD as well as intramuscular injections of BIOBYPASS in patients with severe peripheral vascular disease (PVD) was well tolerated; furthermore, these studies provided some intriguing indications of activity, which led to initiation of major randomized Phase II 'proof-of-concept' studies. This paper provides a review of the rationale behind BIOBYPASS as well as a summary of pertinent preclinical and early clinical data.

Authors:: Rasmussen, Henrik Sandvad; Rasmussen, Camilla Sandvad; Macko, Jennifer

Publication Date:: Sat Jun 01 00:00:00 EDT 2002

OSTI Identifier:: 20650550

Resource Type:: Journal Article

Journal Name:: Cardiovascular Radiation Medicine

Additional Journal Information:: Journal Volume: 3; Journal Issue: 2; Other Information: DOI: 10.1016/S1522-1865(02)00158-0; PII: S1522186502001580; Copyright (c) 2003 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 1522-1865

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; CORONARIES; GENE THERAPY; GROWTH FACTORS; INTRAMUSCULAR INJECTION; PATIENTS; VASCULAR DISEASES

Citation Formats


                    Rasmussen, Henrik Sandvad, Rasmussen, Camilla Sandvad, and Macko, Jennifer. VEGF gene therapy for coronary artery disease and peripheral vascular disease.  United States: N. p., 2002. 
        Web.  doi:10.1016/S1522-1865(02)00158-0.

Copy to clipboard


                    Rasmussen, Henrik Sandvad, Rasmussen, Camilla Sandvad, & Macko, Jennifer. VEGF gene therapy for coronary artery disease and peripheral vascular disease.  United States.  https://doi.org/10.1016/S1522-1865(02)00158-0

Copy to clipboard


                    Rasmussen, Henrik Sandvad, Rasmussen, Camilla Sandvad, and Macko, Jennifer. 2002.  
        "VEGF gene therapy for coronary artery disease and peripheral vascular disease".  United States.  https://doi.org/10.1016/S1522-1865(02)00158-0.

Copy to clipboard


                    
@article{osti_20650550,

  title        = {VEGF gene therapy for coronary artery disease and peripheral vascular disease},

  author       = {Rasmussen, Henrik Sandvad and Rasmussen, Camilla Sandvad and Macko, Jennifer},

  abstractNote = {Coronary artery disease (CAD) and peripheral arterial disease (PAD) are significant medical problems worldwide. Although substantial progress has been made in prevention as well as in the treatment, particularly of CAD, there are a large number of patients, who despite maximal medical treatment have substantial symptomatology and who are not candidates for mechanical revascularization. Therapeutic angiogenesis represents a novel, conceptually appealing treatment option. Ad{sub GV}VEGF121.10 (BIOBYPASS) is an adenovector, carrying the transgene encoding for human vascular endothelial growth factor 121 (VEGF{sub 121}). A number of preclinical studies have demonstrated angiogenic activity of BIOBYPASS, not only anatomically but also functionally. Phase I clinical studies have demonstrated that intramyocardial infection of BIOBYPASS in patients with severe CAD as well as intramuscular injections of BIOBYPASS in patients with severe peripheral vascular disease (PVD) was well tolerated; furthermore, these studies provided some intriguing indications of activity, which led to initiation of major randomized Phase II 'proof-of-concept' studies. This paper provides a review of the rationale behind BIOBYPASS as well as a summary of pertinent preclinical and early clinical data.},

  doi          = {10.1016/S1522-1865(02)00158-0},

  url          = {https://www.osti.gov/biblio/20650550},
  journal      = {Cardiovascular Radiation Medicine},

  issn         = {1522-1865},

  number       = 2,

  volume       = 3,

  place        = {United States},

  year         = {Sat Jun 01 00:00:00 EDT 2002},

  month        = {Sat Jun 01 00:00:00 EDT 2002}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1016/S1522-1865(02)00158-0

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome

Journal Article Green, Melanie; Hiley, Crispin; Shanks, Jonathan; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: Vascular endothelial growth factor (VEGF) is an important hypoxia-inducible pro-angiogenic protein that has been linked with an adverse survival outcome after radiotherapy in other cancer types: we hypothesized that this may also occur in prostate cancer. A retrospective study was, therefore, carried out to evaluate the potential of tumor VEGF expression to predict radiotherapy outcome in patients with high-risk prostate cancer. Methods and Materials: Fifty patients with locally advanced (T3 N0 M0) tumors of Gleason score {>=}6, and who received radiotherapy alone as primary treatment for their disease, were studied. Vascular endothelial growth factor expression was assessed on pretreatmentmore »« less
https://doi.org/10.1016/j.ijrobp.2006.08.077
Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2

Journal Article Miao, H; Hu, Kun; Jimenez, Xenia; ... - Biochemical and Biophysical Research Communications

Compelling evidence suggest that vascular endothelial growth factor (VEGF) and its receptors, especially receptor 2 (VEGFR2, or kinase insert domain-containing receptor, KDR), play a critical role in angiogenesis under both physiological and pathological conditions, including cancer and angiogenic retinopathies such as age-related macular degeneration (AMD). To this end, inhibition of angiogenesis with antagonists to either VEGF or KDR has yielded significant therapeutic efficacy both in preclinical studies in animal models and in clinical trials in patients with cancer and AMD. We previously reported the identification of a high affinity, fully human anti-KDR antibody fragment, 1121B Fab, through a highly stringentmore »« less
https://doi.org/10.1016/j.bbrc.2006.04.119
Hybrid Therapy in Patients with Complex Peripheral Multifocal Steno-obstructive Vascular Disease: Two-Year Results

Journal Article Cotroneo, Antonio; Iezzi, Roberto; Marano, Giuseppe; ... - Cardiovascular and Interventional Radiology

Purpose. To report the 2-year results after hybrid (combined surgical-endovascular) therapy in patients with complex peripheral multifocal steno-obstructive vascular disease. Methods. From September 2001 through April 2003, 47 combined surgical-endovascular procedures were performed in a single session in 44 patients with peripheral occlusive artery disease. Although the common femoral artery is usually treated with open surgery, endoluminal procedures were performed upward in 23 patients (group A), distally in 18 patients (group B), and both upward and downward of the area treated with open surgery in 3 patients (group C). Patients underwent clinical assessment and color duplex ultrasonography examination at 1,more »« less
https://doi.org/10.1007/S00270-005-0296-5
CT-Guided Lumbar Sympathectomy: Results and Analysis of Factors Influencing the Outcome

Journal Article Heindel, Walter; Ernst, Stefan; Manshausen, Gudrun; ... - Cardiovascular and Interventional Radiology

Purpose: To prospectively analyze the effectiveness of computed tomography-guided percutaneous lumbar sympathectomy (CTLS) in patients with peripheral arterial occlusive disease in relation to angiographic findings and vascular risk factors. Methods: Eighty-three patients were treated by CTLS. After clinical evaluation of the risk profile and diagnostic intraarterial digital subtraction arteriography, 14 patients underwent unilateral, and 69 bilateral one-level treatment. Follow-up studies took place on the day following the intervention, after 3 weeks, and after 3 months. Results: A total of 152 interventions were performed in 83 patients. After 3 months, clinical examination of 54 patients (5 patients had died, 24 weremore »« less
https://doi.org/10.1007/S002709900268
Complete revascularization determined by myocardial perfusion imaging could improve the outcomes of patients with stable coronary artery disease, compared with incomplete revascularization and no revascularization

Journal Article Li, Jiehui; Yang, Xiubin; Tian, Yueqin; ... - Journal of Nuclear Cardiology (Online)

Objectives: To compare the outcomes among patients treated by complete coronary revascularization (CCR) or incomplete coronary revascularization (ICR) and no coronary revascularization (NCR) by myocardial perfusion imaging (MPI), as well as to evaluate the impact of severity of ischemia on patients with coronary artery disease (CAD) by different therapy strategies. Background: Using myocardial ischemia severity determined by MPI guiding treatment strategies for CAD patients still lacks strong clinical evidences. Methods: Consecutive patients (N = 286) underwent clinical stress-rest SPECT MPI and were retrospectively followed-up. For assessment of outcome of treatment, all patients were classified into three groups (CCR, ICR, and NCR), andmore »« less
https://doi.org/10.1007/S12350-017-1145-Z

Similar Records